الفهرس Only 14 pages are availabe for public view
 |  | from | 232 |  |  |
| | | from | 232 | | |
Abstract
Levodopa is the first therapeutic strategy for the treatment of Parkinson{u2019}s disease (PD) but motor drawbacks associated with long-term use limit its usefulness, emphasizing the search for other agents. The current study aimed at evaluating the modulatory role of cannabis resin extract in a rotenone model of PD based on a clinical report providing evidence for the amelioration of motor deficits in some PD patients by cannabis. Male Swiss mice received rotenone (1.5 mg/kg/48h, s.c., 6 injections). Cannabis resin extract (5, 10, and 20 mg/kg expressed as x9-tetrahydrocannabinol, i.p.) or levodopa (25 mg/kg, p.o.) was given daily alone or concomitantly with rotenone for 15 days. Rotenone induced marked PD features, characterized by depressed motor behavior, assessed by wire hanging test. This was accompanied by decrease in striatal dopamine, norepinephrine, glutathione, adenosine triphosphate (ATP), Þ-aminobutyric acid (GABA), paraoxonase 1 (PON1) activity, and tyrosine-hydroxylase immunoreactivity (TH-ir).